407 related articles for article (PubMed ID: 21786318)
1. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
van Lierop AH; Hamdy NA; Hamersma H; van Bezooijen RL; Power J; Loveridge N; Papapoulos SE
J Bone Miner Res; 2011 Dec; 26(12):2804-11. PubMed ID: 21786318
[TBL] [Abstract][Full Text] [Related]
2. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers.
van Lierop AH; Hamdy NA; van Egmond ME; Bakker E; Dikkers FG; Papapoulos SE
J Bone Miner Res; 2013 Apr; 28(4):848-54. PubMed ID: 23074140
[TBL] [Abstract][Full Text] [Related]
3. Serum Dickkopf 1 levels in sclerostin deficiency.
van Lierop AH; Moester MJ; Hamdy NA; Papapoulos SE
J Clin Endocrinol Metab; 2014 Feb; 99(2):E252-6. PubMed ID: 24302746
[TBL] [Abstract][Full Text] [Related]
4. Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover.
Yavropoulou MP; van Lierop AH; Hamdy NA; Rizzoli R; Papapoulos SE
Bone; 2012 Jul; 51(1):153-7. PubMed ID: 22579776
[TBL] [Abstract][Full Text] [Related]
5. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
Xu XJ; Shen L; Yang YP; Lu FR; Zhu R; Shuai B; Li CG; Wu MX
Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
[TBL] [Abstract][Full Text] [Related]
6. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
[TBL] [Abstract][Full Text] [Related]
7. Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects.
Huda MS; Durham BH; Wong SP; Dovey TM; McCulloch P; Kerrigan D; Pinkney JH; Fraser WD; Wilding JP
Bone; 2007 Sep; 41(3):406-13. PubMed ID: 17613297
[TBL] [Abstract][Full Text] [Related]
8. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
9. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function.
Piters E; Culha C; Moester M; Van Bezooijen R; Adriaensen D; Mueller T; Weidauer S; Jennes K; de Freitas F; Löwik C; Timmermans JP; Van Hul W; Papapoulos S
Hum Mutat; 2010 Jul; 31(7):E1526-43. PubMed ID: 20583295
[TBL] [Abstract][Full Text] [Related]
10. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.
van Lierop AH; Hamdy NA; van der Meer RW; Jonker JT; Lamb HJ; Rijzewijk LJ; Diamant M; Romijn JA; Smit JW; Papapoulos SE
Eur J Endocrinol; 2012 Apr; 166(4):711-6. PubMed ID: 22267280
[TBL] [Abstract][Full Text] [Related]
11. Elevated Bone Remodeling Markers of CTX and P1NP in Addition to Sclerostin in Patients with X-linked Hypophosphatemia: A Cross-Sectional Controlled Study.
Hansen S; Shanbhogue VV; Jørgensen NR; Beck-Nielsen SS
Calcif Tissue Int; 2019 Jun; 104(6):591-598. PubMed ID: 30710161
[TBL] [Abstract][Full Text] [Related]
12. Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta.
Kocijan R; Muschitz C; Fahrleitner-Pammer A; Amrein K; Pietschmann P; Haschka J; Dinu S; Kapiotis S; Resch H
J Clin Endocrinol Metab; 2014 Feb; 99(2):E311-9. PubMed ID: 24203063
[TBL] [Abstract][Full Text] [Related]
13. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
14. Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment.
van Lierop AH; van der Eerden AW; Hamdy NA; Hermus AR; den Heijer M; Papapoulos SE
J Clin Endocrinol Metab; 2012 Oct; 97(10):E1953-7. PubMed ID: 22844062
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin deficiency is linked to altered bone composition.
Hassler N; Roschger A; Gamsjaeger S; Kramer I; Lueger S; van Lierop A; Roschger P; Klaushofer K; Paschalis EP; Kneissel M; Papapoulos S
J Bone Miner Res; 2014 Oct; 29(10):2144-51. PubMed ID: 24753092
[TBL] [Abstract][Full Text] [Related]
16. Effect of age-related chronic immobility on markers of bone turnover.
Chen JS; Cameron ID; Cumming RG; Lord SR; March LM; Sambrook PN; Simpson JM; Seibel MJ
J Bone Miner Res; 2006 Feb; 21(2):324-31. PubMed ID: 16418789
[TBL] [Abstract][Full Text] [Related]
17. Age-related reference intervals for bone turnover markers from an Australian reference population.
Jenkins N; Black M; Paul E; Pasco JA; Kotowicz MA; Schneider HG
Bone; 2013 Aug; 55(2):271-6. PubMed ID: 23603243
[TBL] [Abstract][Full Text] [Related]
18. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
[TBL] [Abstract][Full Text] [Related]
19. Determinants of bone turnover markers in healthy premenopausal women.
Adami S; Bianchi G; Brandi ML; Giannini S; Ortolani S; DiMunno O; Frediani B; Rossini M;
Calcif Tissue Int; 2008 May; 82(5):341-7. PubMed ID: 18470550
[TBL] [Abstract][Full Text] [Related]
20. Targeting sclerostin as potential treatment of osteoporosis.
Papapoulos SE
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
